MA38277A1 - Anti-lamp1 antibody and drug antibody conjugates, and uses thereof - Google Patents

Anti-lamp1 antibody and drug antibody conjugates, and uses thereof

Info

Publication number
MA38277A1
MA38277A1 MA38277A MA38277A MA38277A1 MA 38277 A1 MA38277 A1 MA 38277A1 MA 38277 A MA38277 A MA 38277A MA 38277 A MA38277 A MA 38277A MA 38277 A1 MA38277 A1 MA 38277A1
Authority
MA
Morocco
Prior art keywords
lamp1
antibodies
present
cancer
increase
Prior art date
Application number
MA38277A
Other languages
French (fr)
Inventor
Francis Blanche
Béatrice Cameron
Tarik Dabdoubi
Yves Baudat
Magali Mathieu
Anne-Marie Lefebvre
Ana Merino-Trigo
Manoel Nunes
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Priority claimed from PCT/EP2013/078017 external-priority patent/WO2014102299A2/en
Publication of MA38277A1 publication Critical patent/MA38277A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

)la présente invention concerne des anticorps qui se lient spécifiquement aux protéines lamp1 (protéine-1 de membrane associée au lysosome) humaines et de macaca fascicularis et des immunoconjugués comprenant lesdits anticorps conjugués ou liés à un agent d'inhibition de la croissance. La présente invention concerne également des compositions pharmaceutiques comprenant des anticorps ou des immunoconjugués de l'invention et l'utilisation des anticorps ou des immunoconjugués pour le traitement du cancer, ainsi que des anticorps anti-lamp1, des acides nucléiques isolés, des vecteurs et des cellules hôtes comprenant une séquence codant pour lesdits anticorps et l'utilisation dudit anticorps en tant qu'outil diagnostic. La présente demande concerne en outre la détection de l'amplification d'un gène lamp1 ou d'une augmentation de cellules cancéreuses conduisant à la détermination de la susceptibilité des patients atteints de cancer à répondre ou non à une thérapie anti-lamp1. La présente invention concerne par conséquent un procédé in vitro de sélection de patients atteints du cancer, ledit procédé comprenant la détermination, dans un échantillon biologique prélevé chez un patient atteint de cancer et comprenant des cellules cancéreuses, de la présence ou non d'une augmentation du nombre de copies du gène lamp1 chez ledit patient; et la sélection du patient sur la base de la présence d'une augmentation du nombre de copies du gène lamp1. La présente invention concerne en outre un agent thérapeutique anti-lamp1 pour son utilisation pour le traitement d'un cancer chez un patient chez qui une augmentation du nombre de copies du gène lamp1 est présente.the present invention relates to antibodies that specifically bind to the human lamp1 (lysosome-associated membrane protein-1) and macaca fascicularis proteins and immunoconjugates comprising said conjugated or growth inhibition agent-linked antibodies. The present invention also relates to pharmaceutical compositions comprising antibodies or immunoconjugates of the invention and the use of antibodies or immunoconjugates for the treatment of cancer, as well as anti-lamp1 antibodies, isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies and the use of said antibody as a diagnostic tool. The present application further relates to the detection of the amplification of a lamp1 gene or an increase of cancer cells leading to the determination of the susceptibility of cancer patients to respond or not to anti-lamp therapy1. The present invention therefore relates to an in vitro method of selecting cancer patients, said method comprising determining, in a biological sample taken from a cancer patient and including cancer cells, the presence or absence of an increase. the number of copies of the lamp1 gene in said patient; and selecting the patient based on the presence of an increase in the number of copies of the lamp1 gene. The present invention further relates to an anti-lamp1 therapeutic agent for use in the treatment of cancer in a patient in whom an increase in the number of copies of the lamp1 gene is present.

MA38277A 2012-12-27 2013-12-26 Anti-lamp1 antibody and drug antibody conjugates, and uses thereof MA38277A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12306691 2012-12-27
PCT/EP2013/078017 WO2014102299A2 (en) 2012-12-27 2013-12-26 Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof

Publications (1)

Publication Number Publication Date
MA38277A1 true MA38277A1 (en) 2018-07-31

Family

ID=47504746

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38277A MA38277A1 (en) 2012-12-27 2013-12-26 Anti-lamp1 antibody and drug antibody conjugates, and uses thereof

Country Status (1)

Country Link
MA (1) MA38277A1 (en)

Similar Documents

Publication Publication Date Title
MA56289A (en) INTERLEUKIN-21 MUTEINS AND METHODS OF TREATMENT
MA46507A1 (en) New cell epitopes and novel combination of cell epitopes for use in immunotherapy of myeloma and other cancers
MA46647A1 (en) New peptides and combination of peptides for use in immunotherapy of pancreatic cancer and other cancers
MA43457A1 (en) Novel peptides, peptide combinations and carriers for use in the immunotherapeutic treatment of various cancers
MA43090A1 (en) Peptides, peptide combinations and cell-based drugs for immunotherapy against urinary bladder cancer and other cancers
MA43435B1 (en) NEW PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS (SEQ ID 25 - MRAX5-003)
Radtke et al. Nail psoriasis–a treatment challenge
MA44551A1 (en) Novel peptides and novel combination of peptides for use in immunotherapy, and methods for generating scaffolds for use against pancreatic cancer and other cancers
MA46022A (en) NEW PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS
MA43719B1 (en) PEPTIDE FOR USE IN IMMUNOTHERAPY AGAINST NON-SMALL CELL LUNG CANCER AND SMALL CELL LUNG CANCER
MA41520B2 (en) New peptides and peptide combination for use in immunotherapy against ovarian cancer and other cancers
WO2016015536A1 (en) Applications of surfactin in cosmetic products and thereof
KR20150080592A (en) Tec family kinase inhibitor adjuvant therapy
TW202014436A (en) Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
MA42294B1 (en) New peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
MA31862B1 (en) Antiseptic antibodies and their uses
Chaudhary et al. Amino acid metabolism inhibits antibody-driven kidney injury by inducing autophagy
ATE283289T1 (en) MONOCLONAL ANTIBODIES, ANTIGENS AND DIAGNOSIS AND THERAPY OF MALIGNANT DISEASES
PH12015501467A1 (en) Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
Wang et al. Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma
Whitley et al. ENTPD1 (CD39) expression inhibits UVR-induced DNA damage repair through purinergic signaling and is associated with metastasis in human cutaneous squamous cell carcinoma
Rocha et al. NLRC4 inflammasome has a protective role on inflammatory bone resorption in a murine model of periodontal disease
ATE529750T1 (en) STIMULATORY AUTOANTIBODIES AGAINST THE PDGF RECEPTOR AS A PATHOLOGICAL MARKER AND THERAPEUTIC TARGET
MA38277A1 (en) Anti-lamp1 antibody and drug antibody conjugates, and uses thereof
Nakagomi et al. Psoriasiform eruption associated with alopecia areata during infliximab therapy